Cologne

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Source

• Recruiting

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· Phase 3· Source

• Recruiting

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· Phase 2· Source

• Recruiting

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· Phase 3· Source

• Recruiting

  NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

  NCT06890273· Source

• Recruiting

  NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

  NCT06494540· Source

• Recruiting

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· Source

• Active, not recruiting

  Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)

  NCT06380738· Source

• Recruiting

  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  NCT06137144· Phase 1/2· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Source

• Recruiting

  Observational Study Protocol: LIVER-R

  NCT06252753· Source

• Active, not recruiting

  A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.

  NCT05637112· Source

• Active, not recruiting

  Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer

  NCT04830709· Source

• Active, not recruiting

  Durvalumab and Tremelimumab for Pediatric Malignancies

  NCT03837899· Phase 1/2· Source

• Active, not recruiting

  Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

  NCT03732820· Phase 3· Source

• Active, not recruiting

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Childhood cancers1 recruiting
• Endometrial cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

  NCT04774380· Phase 3· Source

• Completed

  Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

  NCT02499328· Phase 1/2· Source

• Completed

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· Phase 2· Source

• Completed

  AZD9291 First Time In Patients Ascending Dose Study

  NCT01802632· Phase 1/2· Source

• Completed

  Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

  NCT01078662· Phase 2· Source